載脂蛋白C3(APOC3)活性蛋白
Active Apolipoprotein C3 (APOC3)
Apo-C3; APOCIII; APOC-III
- 編號APB890Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 95%
- 等電點5.8
- 應用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1555 ¥ 3888 ¥ 7776 ¥ 23328 ¥ 58320
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Apolipoprotein C-III?also known as?apo-CIII, and?apolipoprotein C3, is a glycoprotein (consisting of 79 amino acids) that is synthesized principally in the liver. APOC3 is a surface component of chylomicrons, very low density lipoproteins, and high densityl ipoprotein and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. Besides, Apolipoprotein H (APOH) has been identified as an interactor of APOC3, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human APOC3 and recombinant human APOH. Briefly, biotin-linked APOC3 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to APOH-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μl stop solution to the wells and read at 450 nm immediately. The binding activity of recombinant human APOC3 and recombinant human APOH was shown in Figure 1, the EC50?for this effect is 8.5 ug/mL.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
APB890Hu01 | 載脂蛋白C3(APOC3)活性蛋白 | Cell?culture;?Activity?Assays. |
RPB890Hu03 | 載脂蛋白C3(APOC3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB890Hu02 | 載脂蛋白C3(APOC3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB890Hu01 | 載脂蛋白C3(APOC3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB890Hu01 | 載脂蛋白C3(APOC3)多克隆抗體 | WB; ICC; IHC-P; IHC-F; ELISA. |
MAB890Hu22 | 載脂蛋白C3(APOC3)單克隆抗體 | WB; IHC; ICC; IP. |
SEB890Hu | 載脂蛋白C3(APOC3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB890Hu | 載脂蛋白C3(APOC3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Atherosclerosis | Up-reCavia (Guinea pig )lation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure – A possible link between circulating PCSK9 and triacylglycerol concentrations [Pubmed:26978583] |
The Journal of Lipid Research | Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism [Pubmed:27040449] |
Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans [33407555] |